Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Toll-like receptor 2 controls expansion and function of regulatory T cells
Roger P.M. Sutmuller, … , Mihai G. Netea, Gosse J. Adema
Roger P.M. Sutmuller, … , Mihai G. Netea, Gosse J. Adema
Published February 1, 2006
Citation Information: J Clin Invest. 2006;116(2):485-494. https://doi.org/10.1172/JCI25439.
View: Text | PDF
Research Article Immunology

Toll-like receptor 2 controls expansion and function of regulatory T cells

  • Text
  • PDF
Abstract

Tregs play a central role in the suppression of immune reactions and prevention of autoimmune responses harmful to the host. During acute infection, however, Tregs might hinder effector T cell activity directed toward the elimination of the pathogenic challenge. Pathogen recognition receptors from the TLR family expressed by innate immune cells are crucial for the generation of effective immunity. We have recently shown the CD4+CD25+ Treg subset in TLR2–/– mice to be significantly reduced in number compared with WT littermate control mice, indicating a link between Tregs and TLR2. Here, we report that the TLR2 ligand Pam3Cys, but not LPS (TLR4) or CpG (TLR9), directly acts on purified Tregs in a MyD88-dependent fashion. Moreover, when combined with TCR stimulation, TLR2 triggering augmented Treg proliferation in vitro and in vivo and resulted in a temporal loss of the suppressive Treg phenotype in vitro by directly affecting Tregs. Importantly, WT Tregs adoptively transferred into TLR2–/– mice were neutralized by systemic administration of TLR2 ligand during the acute phase of a Candida albicans infection, resulting in a 100-fold reduced C. albicans outgrowth. This demonstrates that in vivo TLR2 also controls the function of Tregs and establishes a direct link between TLRs and the control of immune responses through Tregs.

Authors

Roger P.M. Sutmuller, Martijn H.M.G.M. den Brok, Matthijs Kramer, Erik J. Bennink, Liza W.J. Toonen, Bart-Jan Kullberg, Leo A. Joosten, Shizuo Akira, Mihai G. Netea, Gosse J. Adema

×

Figure 9

Model of TLR2-mediated control of Treg function.

Options: View larger image (or click on image) Download as PowerPoint
Model of TLR2-mediated control of Treg function.
In a preinfection setti...
In a preinfection setting, Treg function is mainly regulated by TCR stimulation and IL-2. During an acute infection, pathogen-derived TLR2 ligands promote proliferation of Tregs paralleled by temporarily abrogated suppression. As a result, Tregs do not suppress the ongoing immune response. Once the pathogen is cleared by the immune system, the source of TLR2 ligands is no longer present, and Tregs will regain their suppressive capabilities, thus contributing to the balance between tolerance and immunity.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts